BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Danese S, D'Amico F, Bonovas S, Peyrin-Biroulet L. Positioning Tofacitinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis. Inflamm Bowel Dis 2018;24:2106-12. [PMID: 29697791 DOI: 10.1093/ibd/izy076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 Magro F, Estevinho MM. Is tofacitinib a game-changing drug for ulcerative colitis? United European Gastroenterol J 2020;8:755-63. [PMID: 32552501 DOI: 10.1177/2050640620935732] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
2 D'Haens GRAM, Lindsay JO, Panaccione R, Schreiber S. Ulcerative Colitis: Shifting Sands. Drugs R D 2019;19:227-34. [PMID: 30827006 DOI: 10.1007/s40268-019-0263-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
3 Ivashkin VT, Shelygin YA, Belousova EA, Abdulganieva DI, Alekseeva OA, Achkasov SI, Valuiskikh EY, Vardanyan AV, Veselov AV, Veselov VV, Golovenko OV, Gubonina IV, Zhigalova TN, Kashnikov VN, Knyazev OV, Makarchuk PA, Moskaliev AI, Nanaeva BA, Nizov AA, Nikitina NV, Nikolaeva NN, Pavlenko VV, Poluektova EA, Svetlova IO, Tarasova LV, Tkachev AV, Frolov SA, Khlynova OV, Chashkova EY, Shapina MV, Sheptulin AA, Shifrin OS, Shchukina OB. PROJECT: CLINICAL GUIDELINES FOR THE DIAGNOSTICS AND TREATMENT OF ULCERATIVE COLITIS. Koloproktologiâ 2019;18:7-36. [DOI: 10.33878/2073-7556-2019-18-4-7-36] [Cited by in Crossref: 16] [Cited by in F6Publishing: 1] [Article Influence: 5.3] [Reference Citation Analysis]
4 Rogler G. Efficacy of JAK inhibitors in Crohn's Disease. J Crohns Colitis 2020;14:S746-54. [PMID: 31781755 DOI: 10.1093/ecco-jcc/jjz186] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
5 Tran V, Shammas RM, Sauk JS, Padua D. Evaluating tofacitinib citrate in the treatment of moderate-to-severe active ulcerative colitis: design, development and positioning of therapy. Clin Exp Gastroenterol 2019;12:179-91. [PMID: 31118734 DOI: 10.2147/CEG.S150908] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]